Diagnostic performance of serum origin recognition complex subunit 1 protein for hepatitis B virus-related hepatocellular carcinoma

Table 1 The characteristics of study subjects, n (%)/mean ± SD

Group	Subgroup	Number	Male	Age (year)	ALT (U/L)	AST (U/L)	ORC1 (ng/L)	ESPL1 (ng/L)	AFP (ng/mL)
HBV-infected group	HBV-S-Int	20	17 (85.0)	44.35 ± 8.06	29.70 ± 14.03	33.45 ± 8.70	1660.65 (1428.60, 2218.60)	484.58 (300.22, 553.09)	3.04 (1.70, 8.19)
	HBV-NS-Int	47	33 (70.2)	51.14 ± 9.86	25.21 ± 13.64	30.17 ± 9.03	954.75 (681.19, 1435.25)	231.41 (189.15, 281.58)	2.5 (1.69, 3.23)
	CHB	162	109 (67.3)	42.45 ± 10.07	23.00 ± 10.66	29.31 ± 16.96	914.68 (642.23, 1319.14)	198.34 (151.29, 260.22)	2.39 (1.92, 315)
	HBV-LC	154	121 (78.6)	47.31 ± 9.67	31.94 ± 19.73	37.31 ± 20.40	918.30 (638.24, 1466.50)	276.14 (220.62, 327.27)	2.45 (1.82, 3.89)
	HBV-HCC	96	85 (88.5)	49.13 ± 9.44	50.5 ± 47.13	50.69 ± 41.41	1077.07 (727.03, 1675.67)	439.00 (261.25, 641.72)	10.55 (3.61, 263.81)
Non-HBV-infected control group	Non-HBV-HCC	29	19 (65.5)	59.34 ± 9.98	24.48 ± 12.85	34.69 ± 16.81	749.54 (660.24, 1150.33)	245.62 (212.75, 438.93)	60.22 (3.62, 2842.69)
	Healthy control	44	21 (47.7)	38.18 ± 13.33	-	-	731.51 (503.39, 1043.57)	128.89 (105.02, 150.82)	-

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ORC1: Origin recognition complex subunit 1; ESPL1: Extra spindle pole bodies-like 1; AFP: Alpha-fetoprotein; HBV-S-Int: Hepatitis B virus S gene integration; HBV-NS-Int: Hepatitis B virus non-S gene integration; CHB: Chronic hepatitis B; HBV-LC: Hepatitis B virus-related liver cirrhosis; HBV-HCC: Hepatitis B virus-related hepatocellular carcinoma.